Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Absolute Bioavailability of Abrocitinib in Healthy Men
NCT03250039Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Primary endpoint: Cumulative recovery of radioactivity in urine and feces at Day 14. Started Jul 2017; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03250039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250039.